BriaCell Therapeutics Corp.
- Home
- Companies
- BriaCell Therapeutics Corp.
- Products
- BriaCell - Model Bria-OTS - ...
BriaCell - Model Bria-OTS - Off-the-Shelf Personalized Immunotherapy Cell Lines
We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type. We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, allowing for matching of over 99% of patients with advanced breast cancer. A simple saliva test is used to determine the HLA-type of each patient.
Most popular related searches
immunotherapy
prostate cancer
lung cancer
saliva test
cellular immunotherapy
breast cancer
immunotherapy treatment
cell line development
clinical study
cancerous breast
- Each patient will then be treated with the appropriate pre-manufactured Bria-OTS™ formulation.
- Similar cell lines are in development for prostate cancer, lung cancer, and melanoma.
- A pre-clinical Cooperative Research and Development Agreement (CRADA) is in place with the National Cancer Institute (NCI) in the U.S. to investigate the Bria-OTS™ mechanism of action.
- This approach allows personalized treatment without the need for personalized manufacturing. Additionally, it saves time and skips expensive and complicated manufacturing procedures associated with other personalized immunotherapy treatments.